Crossmark

[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice

Crossref DOI link: https://doi.org/10.1016/j.farma.2024.12.007

Published Print: 2025-02

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Choví-Trull, Maria

Megías-Vericat, Juan Eduardo

Boix, Santiago Bonanad

Guaita, Saturnino Haya

Haro, Ana Rosa Cid

Rodriguez, Marta Aguilar

Andrés, Jose Luis Poveda
Funding

Funding for this research was provided by:

McMaster University
License Information

Text and Data Mining valid from 2025-02-01

Text and Data Mining valid from 2025-02-01

Version of Record valid from 2024-12-24
More Information

This article is maintained by: Elsevier

Article Title: [Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice

Journal Title: Farmacia Hospitalaria

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.farma.2024.12.007

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.farma.2024.10.005

Content Type: article

Copyright: © 2024 Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below